Prognostic and predictive impact of molecular tumor burden index in non‐small cell lung cancer patients

BACKGROUND: The biomarkers of immune checkpoint inhibitors in the treatment of non‐small cell lung cancer (NSCLC) patients have limited predictive performance. In this study we aimed to investigate the feasibility of molecular tumor burden index (mTBI) in circulating tumor DNA (ctDNA) as a predictor...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Fan, Tang, Min, Cui, Liang, Bai, Jing, Yu, Jiangyong, Gao, Jiayi, Nie, Xin, Li, Xu, Xia, Xuefeng, Yi, Xin, Zhang, Ping, Li, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626252/
https://www.ncbi.nlm.nih.gov/pubmed/37724484
http://dx.doi.org/10.1111/1759-7714.15098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626252/
https://www.ncbi.nlm.nih.gov/pubmed/37724484
http://dx.doi.org/10.1111/1759-7714.15098

Ejemplares similares